Dementia-Related Epilepsy in Vascular Dementia and Alzheimer’s Disease

Slides:



Advertisements
Similar presentations
Frontotemporal Dementia
Advertisements

Psychiatric presentation of Alzheimer’s in Jordan Preliminary survey Jamal Khatib MD Consultant Psychiatrist Jordanian Alzheimer Association.
Estate Planning and the Neuropsychologist
GAL-INT-6 The safety and efficacy of galantamine in patients with Vascular dementia or AD with cerebrovascular disease Sean Lilienfeld MD, FCP, MMed Janssen.
A 67-year-old male with behavioral and language problems
Glucose Levels and Risk of Dementia Presented by - Anas Kabaha, MD Sheba medical center Sheba medical center August 8,2013.
Non-medication Management of Agitated Behavior in Dementia Patients Josepha A. Cheong, MD University of Florida Departments of Psychiatry and Neurology.
Parkinson’s Plus By: Glen Estrosos.
Jack Twersky, MD Medical Director CLC Durham.  Memory impairment and at least one of the following  Aphasia  Apraxia  Agnosia  Executive function.
“3 D’s” of Geriatrics Dementia, Delirium, and Depression These common disorders can look alike. GAI often helps uncover or differentiate them. All are.
MCI Conversion to Dementia: Clinic and Community-Based Studies
Lecture 9: Analysis of intervention studies Randomized trial - categorical outcome Measures of risk: –incidence rate of an adverse event (death, etc) It.
Adverse Outcomes After Hospitalization and Delirium in Persons with Alzheimer Disease Charles Wang, PharmD Candidate.
Non Alzheimer's Dementias Elizabeth Landsverk, MD Geriatrician, ElderConsult Geriatric Medicine Adjunct Professor of Medicine, Stanford University.
Dementia Screening at Stonehaven Medical Group Dr. Claire Johnston, Stonehaven Medical Group 2014 Part 1 - Audit Introduction The author recognised that.
Mariano Musacchio 1 François Sellal 2 Frédéric Blanc 2 Jean-Marc Michel 2 Stephan Kremer 3 Jean-Louis Dietemann 3 1 Department of Neuroradiology - CHG.
CPC #7: Pathology Barbara J. Crain, MD, PhD February 25, 2009.
EBM --- Journal Reading Presenter :黃美琴 Date : 2005/10/27.
Peripheral Artery Disease in Orthopaedic Patients with Asymptomatic Popliteal Artery Calcification on Plain X-ray Adam Podet, MS; Julia Volaufova, phD,;
BREAST CANCER BY STAGE OF DISEASE AT DIAGNOSIS, CENTRAL OKLAHOMA Arthur Owora, MPH; Aaron Wendelboe, PhD; David Thompson, PhD; Janis Campbell, PhD The.
Comparison of Risk Factors for Early-Onset versus Late-Onset Alzheimer Disease OBJECTIVE To compare early-onset (before 65) Alzheimer disease (AD) patients.
©2015 MFMER | slide-1 The Effect of an Automated Point of Care Tool on Diagnosis and Management of Childhood Obesity in Primary Care Natalie Gentile, MD.
DEMENTIA 1/6/16 DR TONY O’BRIEN MD FRCP. Dementia Common – 700,000 sufferers in the UK Common – 700,000 sufferers in the UK Prevalence increases with.
R1. 이용석 / modulator pf. 동석호. Introduction Acute pancreatitis(AP) ▫most common disease that affects the pancreas ▫incidence of AP varies globally, affecting.
The Attention-Deficit Hyperactivity Disorder Paradox: 2
Anne Moore Specialist in Special Care NHS Lanarkshire PDS
J Browne, DA Edwards, KM Rhodes, DJ Brimicombe, RA Payne
Value of cerebrospinal fluid visinin-like protein-1 (VILIP-1) for prediction of mild cognitive impairment progression to Alzheimer's disease  Mirjana Babić.
Dement Geriatr Cogn Disord 2011;31:239– DOI: /
Dementia Jaqueline Raetz, M.D..
Metabolic Syndrome and Progression of Mild Cognitive Impairment
Quality of Electronic Emergency Department Data: How Good Are They?
Table 1. Summary of Study Measures
Copyright © 2000 American Medical Association. All rights reserved.
Using the Disease State Fingerprint Tool for Differential Diagnosis of Frontotemporal Dementia and Alzheimer's Disease Dement Geriatr Cogn Disord Extra.
Use of Amyloid PET Scan in Early Diagnosis of Alzheimer’s Disease in a Secondary Care Memory Clinic Niki Schoonenboom, MD PhD1, Mohammed Akarriou, MD2;
Preventive Effect of Rifampicin on Alzheimer Disease Needs at Least 450 mg Daily for 1 Year: An FDG-PET Follow-Up Study - DOI: / Fig. 1.
Cerebral Microvascular Accumulation of Tau Oligomers in Alzheimer#cod#x02019;s Disease and Related Tauopathies Diana L Castillo-Carranza 1, 2 ;Ashley N.
Effect of centrally acting ACE inhibitors on Alzheimer’s disease progress: A retrospective longitudinal study using SLAM BRC Case register Dr Gayan Perera.
#14-A-1124 AAN Department of Neurology and Epidemiology, University of Oklahoma Medical Center; Oklahoma City, OK Cognitive and Behavioral Changes in PSP:
1: Houston Methodist Neurological Institute, Houston, TX
Presentation for the SCTR Scientific Retreat on Aging Related Research
Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Unit 40 Dementia care.
Dementia Jaqueline Raetz, M.D..
Frontotemporal dementia syndromes are united by underlying frontotemporal lobar degeneration pathology, which can be divided according to the presence.
Fig. 11. Algorithm for differential diagnosis of cognitive impaired subjects by employing structural imaging. AD = Alzheimer's disease, BG = basal ganglia,
What will it take to develop an effective Alzheimer’s drug?
autoimmune disorders in Iraq and Afghanistan Veterans
Presenter : Dr Aneelraj Co investigators : Dr Srikala Bharath
פסיכוגריאטריה ד''ר שורצמן בי''ח פלימן.
Imaging AD Progression Amyloid Imaging Agents.
Clinical Spectrum, Risk Factors, and Behavioral Abnormalities among Dementia Subtypes in a North Indian Population: A Hospital-Based Study Dement Geriatr.
Cognitive Disorders and Aging
Baseline characteristics of HPS participants by prior diabetes
Mark S. Forman, Virginia M-Y. Lee, John Q. Trojanowski  Neuron 
Ross operation: 16-year experience
Younger women with symptomatic peripheral arterial disease are at increased risk of depressive symptoms  Kim G. Smolderen, PhD, John A. Spertus, MD, MPH,
Transmissible human proteopathies: an expanding field
Prevalence and incidence of clinically diagnosed Alzheimer's disease dementia from 1994 to 2012 in a population study  Kumar B. Rajan, Jennifer Weuve,
Prevalence and incidence of clinically diagnosed Alzheimer's disease dementia from 1994 to 2012 in a population study  Kumar B. Rajan, Jennifer Weuve,
Predictive value of the National Institutes of Health Stroke Scale and the Mini-Mental State Examination for neurologic outcome after coronary artery.
Dementia and Cerebrovascular Disease
Cancer is not a risk factor for bullous pemphigoid
Neuropathologic, genetic, and longitudinal cognitive profiles in primary age-related tauopathy (PART) and Alzheimer's disease  W. Robert Bell, Yang An,
Finding Sex Partners On-Line: What’s the Risk for STI
Association between hidradenitis suppurativa and hospitalization for psychiatric disorders: A cross-sectional analysis of the National Inpatient Sample.
Receiver operating characteristics curves showing discrimination between patients with dementia of the Alzheimer type (at time of diagnosis) and non-demented.
Fig. 1. ROC curve for K-IADL to diagnose dementia or MCI
Impact of approaches for clinical and radiological monitoring on predicting of short-term and long-term disability outcomes in multiple sclerosis Brian.
Presentation transcript:

Dementia-Related Epilepsy in Vascular Dementia and Alzheimer’s Disease Tyler Webb, MD; David Thompson, PhD; Summer Frank; Jennifer Lippoldt, MPH; Linda Hershey, MD Department of Neurology, University of Oklahoma Medical Center; Oklahoma City, OK METHODS This study consisted of a two-year, retrospective review of 195 charts of patients with varying dementia diagnoses, including vascular dementia (VaD), Alzheimer’s disease (AD), dementia with Lewy bodies (DLB), and the various tauopathies (Tau). The tauopathies were grouped into one category due to the relatively low number of patients with these diagnoses and included progressive supranuclear palsy, frontotemporal dementia and corticobasal degeneration. The patients’ ages were 50-90 years, and the diagnosis of epilepsy (if present) was within 5 years of the onset of dementia. Two Mini Mental Status Exam (MMSE) scores separated by greater than 9 months were used to estimate the progression of dementia and were adjusted for time from dementia diagnosis. OBJECTIVE We asked whether epilepsy was more common in patients with vascular dementia, Alzheimer’s disease, or other dementia subtypes. We also asked whether those with dementia-related epilepsy exhibited a more rapidly progressive course than those who were seizure-free, and if epilepsy developed earlier in the course of vascular dementia. BACKGROUND Seizures have a well-known and well-documented association with Alzheimer's disease when compared to age-matched controls. However the association, or lack thereof, between seizures and other neurodegenerative diseases has not been as clearly elucidated. We were particularly interested in the observation that seizures seem to be more common among those with vascular dementia and that they seemed to develop epilepsy earlier in the course of their disease. In a retrospective chart review of patients with multiple dementia types we looked at the prevalence of the comorbid diagnosis of epilepsy. We also studied when in the course of their disease the seizures developed and how the presence of epilepsy altered the progression of their dementia. Fig. 2 Decline of MMSE scores after a minimum of 9- month follow-up among those with and without epilepsy revealed a significantly more rapid decline in the epilepsy group Fig. 3 Time to event curves showing a shorter time course of dementing illness before the development of seizures among those patients with vascular dementia compared with those who had Alzheimer’s disease % of dementia Patients RESULTS The prevalence of epilepsy [fig. 1] in VaD (20.0%; exact binomial 95%CI: 7.7%, 38.6%) did not differ significantly compared to that seen in AD (2.9%; exact binomial 95%CI: 0.6%, 8.3%). Patients with dementia-related epilepsy exhibited a significantly more rapid decline of MMSE scores (1.75 points/year with 95% CI: 0.59, 2.91), compared to the seizure-free group (0.51 points/year with 95% CI: 0.22, 0.80) [fig. 2]. Time to event curves among those with and without epilepsy showed that patients with VaD developed epilepsy earlier than those with AD (logrank test p=0.0022) [fig. 3]. Fig. 1 The prevalence of epilepsy categorized by dementia type did not differ significantly between each group. Confidence intervals are shown in red and are based on a CI of 95%. Conclusion: Epilepsy prevalence does not differ significantly among various dementia subtypes, but those with VaD develop epilepsy earlier than those with AD. Patients with dementia-related epilepsy have a more rapid decline than those who are seizure-free. Last Edited: September 2, 2013 Author Disclosures: none Email: tyler-webb@ouhsc.edu